Takeda Pharmaceutical Stock Forecast, Price & News

-0.22 (-1.28 %)
(As of 09/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.50 million shs
Average Volume2.69 million shs
Market Capitalization$53.80 billion
P/E Ratio11.64
Dividend Yield3.95%
30 days | 90 days | 365 days | Advanced Chart
Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Takeda Pharmaceutical logo

About Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.69 out of 5 stars

Medical Sector

918th out of 1,352 stocks

Pharmaceutical Preparations Industry

454th out of 665 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Takeda Pharmaceutical?

Wall Street analysts have given Takeda Pharmaceutical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,810,000 shares, an increase of 28.3% from the August 15th total of 4,530,000 shares. Based on an average trading volume of 1,790,000 shares, the short-interest ratio is currently 3.2 days. Currently, 0.2% of the shares of the company are sold short.
View Takeda Pharmaceutical's Short Interest

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Takeda Pharmaceutical

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its earnings results on Friday, July, 30th. The company reported $0.51 EPS for the quarter. The business earned $8.68 billion during the quarter. Takeda Pharmaceutical had a net margin of 14.69% and a trailing twelve-month return on equity of 13.00%.
View Takeda Pharmaceutical's earnings history

How has Takeda Pharmaceutical's stock been impacted by COVID-19?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TAK shares have decreased by 0.9% and is now trading at $17.00.
View which stocks have been most impacted by COVID-19

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.68 per share and currently has a dividend yield of 3.95%. The dividend payout ratio of Takeda Pharmaceutical is 34.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 72.34% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.
View Takeda Pharmaceutical's dividend history.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2021 earnings guidance on Friday, August, 6th. The company provided earnings per share (EPS) guidance of $3.590-$3.590 for the period. The company issued revenue guidance of $30.67 billion-$30.67 billion.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Christophe Weber, President, CEO & Representative Director
  • Constantine Saroukos, Chief Financial Officer & Director
  • Andrew S. Plump, Director, Research & Development President
  • Michael E. Mendelsohn, Chief Medical & Scientific Officer
  • Norimasa Takeda, Chief Accounting Officer & Corporate Controller

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (0.49%), Price T Rowe Associates Inc. MD (0.17%), Macquarie Group Ltd. (0.15%), Northern Trust Corp (0.13%), Parametric Portfolio Associates LLC (0.12%) and Mondrian Investment Partners LTD (0.12%).

Which institutional investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, GMT Capital Corp, Susquehanna International Group LLP, Renaissance Technologies LLC, Capula Management Ltd, Bank of America Corp DE, Northern Trust Corp, and First Trust Advisors LP.

Which institutional investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Polygon Management Ltd., LMR Partners LLP, Macquarie Group Ltd., Oasis Management Co Ltd., HAP Trading LLC, Manning & Napier Group LLC, and Brandes Investment Partners LP.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $17.00.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $53.80 billion and generates $30.17 billion in revenue each year. The company earns $3.53 billion in net income (profit) each year or $1.98 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 2,021 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111.

This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.